John W. Hanna is President and CEO of CareDx, Inc., the leading transplant patient diagnostics company based in Brisbane, California. Appointed in April 2024, he brings over two decades of executive leadership in molecular diagnostics and life sciences, including a decade at Veracyte and a stint as CEO of Apton Biosystems. At CareDx, he is executing a bold three-year plan targeting $500 million in revenue and 20% adjusted EBITDA by 2027, transforming the company from a single-test diagnostics business into a full clinical ecosystem for transplant centers worldwide.
Mike Rosenbluth is the Founder and CEO of Swing Therapeutics, the San Francisco-based company behind Stanza - the first FDA-authorized prescription digital therapeutic for fibromyalgia symptoms. A Stanford-trained mechanical engineer with a UC Berkeley PhD in Bioengineering, Rosenbluth spent years at McKinsey, a VC firm (Versant Ventures), and cancer diagnostics company Veracyte before founding Swing in 2019. His company's landmark PROSPER-FM Phase 3 trial results were published in The Lancet in 2024, and Swing has raised over $30 million to bring evidence-based, non-drug behavioral therapy to the estimated 4 million Americans with fibromyalgia.